Exagen Inc (XGN)

$2.78 -0.19 (-6.40%)
Market Cap 66.87M
Revenue (ttm) 66.58M
Net Income (ttm) -19.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -29.96%
Debt to Equity Ratio 1.31
Volume 382,000
Avg Vol 510,392
Day's Range N/A - N/A
Shares Out 24.05M
Stochastic %K 3%
Beta 1.88
Analysts Strong Sell
Price Target $9.50

Company Profile

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative o...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 760 560 1501
Address:
1261 Liberty Way, Suite C, Vista, United States
Abdul92z
Abdul92z Mar. 21 at 12:19 PM
$XGN 👀
0 · Reply
anachartanalyst
anachartanalyst Mar. 11 at 7:02 PM
$XGN https://anachart.com/wp-content/uploads/ana_temp/1773255719_soc-img.jpg
0 · Reply
anachartanalyst
anachartanalyst Mar. 11 at 2:01 PM
$XGN https://anachart.com/wp-content/uploads/ana_temp/1773237686_soc-img.jpg
0 · Reply
d_risk
d_risk Mar. 10 at 6:26 PM
$XGN - Exagen Inc - 10K - Updated Risk Factors XGN adds new risks from volatile US trade policy and tariffs, expanded detail on government shutdowns and agency underfunding, heavier public-company compliance burdens, and a new $65M secured term loan with restrictive covenants and collateral over most assets, heightening financing and operational constraint risks. #HealthcareSector #TradePolicyRisk #GovernmentShutdown #FinancingConstraints #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/XGN/10-K/2026-03-10
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 4:17 PM
$XGN Current Stock Price: $3.54 Contracts to trade: $5.0 XGN Mar 20 2026 Call Entry: $0.59 Exit: $0.84 ROI: 43% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 10 at 1:24 PM
$XGN Q4 '25 Earnings Results & Recap Exagen believes it is well positioned to deliver continued revenue growth and positive Adjusted EBITDA in the next 12-18 months, indicating an optimistic outlook for financial performance.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 10 at 1:24 PM
$XGN Q4 '25 Earnings Results & Recap Exagen Inc. believes it is well positioned to deliver continued revenue growth and positive Adjusted EBITDA in the next 12-18 months, with ongoing investments in R&D for new testing products.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 1:51 AM
$XGN RSI: 29.76, MACD: -0.5866 Vol: 0.50, MA20: 3.72, MA50: 5.16 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SignalPathfinder
SignalPathfinder Feb. 18 at 9:49 AM
$XGN Low-liquidity ticker dominated by speculative trading.
0 · Reply
anachartanalyst
anachartanalyst Feb. 17 at 12:01 PM
$XGN https://anachart.com/wp-content/uploads/ana_temp/1771329676_soc-img.jpg
0 · Reply
Latest News on XGN
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 6:50 PM EDT - 11 days ago

Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Mar 10, 2026, 8:00 AM EDT - 11 days ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. to Participate in Upcoming Investor Conferences

Mar 3, 2026, 9:00 AM EST - 18 days ago

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

Feb 24, 2026, 9:00 AM EST - 25 days ago

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Jan 11, 2026, 3:00 PM EST - 2 months ago

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Nov 11, 2025, 9:00 AM EST - 4 months ago

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 3:56 PM EST - 4 months ago

Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript

Exagen Inc. Reports Strong Q3 2025 Results

Nov 4, 2025, 8:00 AM EST - 4 months ago

Exagen Inc. Reports Strong Q3 2025 Results

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

Oct 23, 2025, 9:15 AM EDT - 5 months ago

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

Oct 21, 2025, 4:05 PM EDT - 5 months ago

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

Exagen Inc. to Participate in Third Quarter Investor Conferences

Aug 6, 2025, 4:05 PM EDT - 8 months ago

Exagen Inc. to Participate in Third Quarter Investor Conferences

Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 3:09 PM EDT - 8 months ago

Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript

Exagen Inc. Reports Strong Q2 2025 Results

Jul 29, 2025, 8:00 AM EDT - 8 months ago

Exagen Inc. Reports Strong Q2 2025 Results

Exagen Inc. Appoints Chas McKhann to Board of Directors

Jul 17, 2025, 4:05 PM EDT - 8 months ago

Exagen Inc. Appoints Chas McKhann to Board of Directors

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

Jul 15, 2025, 4:05 PM EDT - 8 months ago

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

Jun 23, 2025, 9:00 AM EDT - 9 months ago

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

May 9, 2025, 4:05 PM EDT - 11 months ago

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Exagen Inc. Prices Public Offering of Common Stock

May 8, 2025, 8:30 AM EDT - 11 months ago

Exagen Inc. Prices Public Offering of Common Stock

Exagen Inc. Announces Proposed Public Offering of Common Stock

May 7, 2025, 4:05 PM EDT - 11 months ago

Exagen Inc. Announces Proposed Public Offering of Common Stock

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:51 PM EDT - 11 months ago

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

May 5, 2025, 8:00 AM EDT - 11 months ago

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

Apr 28, 2025, 9:00 AM EDT - 11 months ago

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability

Apr 26, 2025, 3:31 AM EDT - 11 months ago

Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

Apr 21, 2025, 4:05 PM EDT - 11 months ago

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 1:13 PM EDT - 1 year ago

Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

Feb 25, 2025, 4:05 PM EST - 1 year ago

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Jan 12, 2025, 12:00 PM EST - 1 year ago

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Dec 12, 2024, 9:00 AM EST - 1 year ago

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Nov 14, 2024, 4:30 PM EST - 1 year ago

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 1:09 PM EST - 1 year ago

Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Oct 21, 2024, 4:05 PM EDT - 1 year ago

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 10:49 AM EDT - 1 year ago

Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 2, 2024, 9:00 AM EDT - 1 year ago

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

Jul 22, 2024, 9:00 AM EDT - 1 year ago

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

Time to Play 5 Top-Ranked Stocks With Rising P/E?

Jun 10, 2024, 1:14 PM EDT - 1 year ago

Time to Play 5 Top-Ranked Stocks With Rising P/E?

AMC BNBX HCAT YOU

Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript

May 13, 2024, 11:25 AM EDT - 2 years ago

Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

May 13, 2024, 8:00 AM EDT - 2 years ago

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

Exagen to Announce First Quarter 2024 Results on May 13, 2024

Apr 30, 2024, 4:05 PM EDT - 2 years ago

Exagen to Announce First Quarter 2024 Results on May 13, 2024

Exagen Inc. Announces Changes to the Board of Directors

Apr 26, 2024, 8:30 AM EDT - 2 years ago

Exagen Inc. Announces Changes to the Board of Directors

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 1:23 PM EDT - 2 years ago

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 8, 2024, 9:00 AM EST - 2 years ago

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Mar 7, 2024, 4:05 PM EST - 2 years ago

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Jan 7, 2024, 12:00 PM EST - 2 years ago

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript

Nov 20, 2023, 8:37 AM EST - 2 years ago

Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript

Exagen Inc. Reports Strong Third Quarter 2023 Results

Nov 13, 2023, 4:05 PM EST - 2 years ago

Exagen Inc. Reports Strong Third Quarter 2023 Results

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

Nov 9, 2023, 4:05 PM EST - 2 years ago

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

Abdul92z
Abdul92z Mar. 21 at 12:19 PM
$XGN 👀
0 · Reply
anachartanalyst
anachartanalyst Mar. 11 at 7:02 PM
$XGN https://anachart.com/wp-content/uploads/ana_temp/1773255719_soc-img.jpg
0 · Reply
anachartanalyst
anachartanalyst Mar. 11 at 2:01 PM
$XGN https://anachart.com/wp-content/uploads/ana_temp/1773237686_soc-img.jpg
0 · Reply
d_risk
d_risk Mar. 10 at 6:26 PM
$XGN - Exagen Inc - 10K - Updated Risk Factors XGN adds new risks from volatile US trade policy and tariffs, expanded detail on government shutdowns and agency underfunding, heavier public-company compliance burdens, and a new $65M secured term loan with restrictive covenants and collateral over most assets, heightening financing and operational constraint risks. #HealthcareSector #TradePolicyRisk #GovernmentShutdown #FinancingConstraints #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/XGN/10-K/2026-03-10
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 4:17 PM
$XGN Current Stock Price: $3.54 Contracts to trade: $5.0 XGN Mar 20 2026 Call Entry: $0.59 Exit: $0.84 ROI: 43% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 10 at 1:24 PM
$XGN Q4 '25 Earnings Results & Recap Exagen believes it is well positioned to deliver continued revenue growth and positive Adjusted EBITDA in the next 12-18 months, indicating an optimistic outlook for financial performance.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 10 at 1:24 PM
$XGN Q4 '25 Earnings Results & Recap Exagen Inc. believes it is well positioned to deliver continued revenue growth and positive Adjusted EBITDA in the next 12-18 months, with ongoing investments in R&D for new testing products.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 1:51 AM
$XGN RSI: 29.76, MACD: -0.5866 Vol: 0.50, MA20: 3.72, MA50: 5.16 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SignalPathfinder
SignalPathfinder Feb. 18 at 9:49 AM
$XGN Low-liquidity ticker dominated by speculative trading.
0 · Reply
anachartanalyst
anachartanalyst Feb. 17 at 12:01 PM
$XGN https://anachart.com/wp-content/uploads/ana_temp/1771329676_soc-img.jpg
0 · Reply
totumfaktum88
totumfaktum88 Feb. 11 at 3:20 PM
$XGN More and more new and large positions. Active short.
0 · Reply
HiddenSentiment
HiddenSentiment Feb. 10 at 1:56 PM
$XGN is a genomics or biotech company; early-stage and high-risk.
0 · Reply
totumfaktum88
totumfaktum88 Feb. 4 at 3:32 PM
$XGN Someone is not finished with the sells. Every new position has been sold so far.
1 · Reply
totumfaktum88
totumfaktum88 Feb. 4 at 3:30 PM
$XGN Not yet.
3 · Reply
Mike_Rotsch
Mike_Rotsch Feb. 3 at 9:08 PM
$XGN Shorts have been covering ahead of this incoming surge.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 9:44 PM
$XGN RSI: 12.68, MACD: -0.7262 Vol: 0.85, MA20: 4.97, MA50: 6.16 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
totumfaktum88
totumfaktum88 Feb. 2 at 11:08 AM
$XGN The sell off will continues this week based on the shortable shares data. Institutional buys are started on thursday and friday, but every new open is sold. We will see a trend change in March maybe.
0 · Reply
Mike_Rotsch
Mike_Rotsch Feb. 2 at 12:34 AM
$XGN Two things: 1. Current price is now equidistant to the daily 200EMA, as the 26 October peak. This puts it squarely in the pivot zone. In a literal way. 2. I found this using my own indicator on Pine Screener, that scans for conditions like these. But this is absolutely perfect. Standing by, waiting to enter. I would expect this to pivot anytime starting now, to about 2 weeks out, at the latest.
1 · Reply
totumfaktum88
totumfaktum88 Jan. 30 at 3:15 PM
$XGN I’m wondering, what if someone just want buy the company with a discount price? This kind of agressive control just unusual. The RSI is continuesly oversold for 2 month now. IMO it will fall to $2.5. Other idea, someone just want to bleed out the company.
0 · Reply
totumfaktum88
totumfaktum88 Jan. 27 at 3:29 PM
$XGN They are forcing the price to 52 week low or lower without question but without any reasonable choice. "Punch the kid if he let it." Turn your seatbelts and welcome the 3s and 2s.
0 · Reply
totumfaktum88
totumfaktum88 Jan. 26 at 4:18 PM
$XGN Canaccord reiterated their price target ($15 ) with a buy btw.
0 · Reply
totumfaktum88
totumfaktum88 Jan. 26 at 2:37 PM
$XGN In short: everyone say good about it, but a +20% q4 and yoy earning wasnt enough. MMs waiting for the q4 meeting, meanwhile they are letting fall like a knife.
1 · Reply